Takeda Collaborates with Evotec on RNA Targeting Drug Development
Shots:
- Evotec to receive research funding and will be eligible for $160M/program as discovery- pre/ clinical- a commercial milestone along with royalties on sales of product emerges from the collaboration
- The collaboration will utilize Evotec’s RNA targeting platform to identify RNA sequences to target with small-molecule ligands aligned that can be developed into the first-in-class therapeutics
- The companies will jointly identify & develop small molecules targeting a range of RNA targets aligned with Takeda’s research and development areas
Ref: Evotec | Image: Wikipedia
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com